Service Quote Request
Please fill out the form below with your detailed inquiry.
-
PHONE: 1-866-918-6812
Why Is AAV2 So Difficult to Produce at High Yield?
Obtaining very high yields of Adeno-Associated Virus serotype 2 (AAV2) can be considerably more challenging than producing many other commonly used AAV serotypes. This is largely due to the unique biological properties of the AAV2 capsid and serotype-dependent differences in vector production, release, and recovery.
Strong Cellular Retention and Limited Release
One of the major challenges with AAV2 production is its strong affinity for heparan sulfate proteoglycans (HSPGs) on the surface of producer cells.
Unlike serotypes such as AAV8 and AAV9, which can release a substantial fraction of newly produced viral particles into the culture medium, AAV2 particles tend to remain strongly associated with producer cells and cellular material.
As a result, efficient AAV2 recovery generally requires extensive cell harvesting and lysis. This strong cellular association can also make downstream recovery and purification less efficient, ultimately reducing the amount of purified vector obtained from a production batch.
Relatively Low Vector Productivity
AAV production efficiency is highly dependent on the serotype. Under comparable production conditions, AAV2 can exhibit substantially lower recoverable vector-genome yields than high-producing serotypes such as AAV8 or AAV9.
Therefore, achieving very high AAV2 titers—particularly when a large total number of vector genomes is required—may require significantly more starting material and careful optimization of the production, harvesting, and purification processes.
Empty and Partially Packaged Capsids
Formation of an AAV capsid does not necessarily mean that a complete vector genome has been successfully packaged.
Depending on the vector construct and production conditions, AAV2 preparations can contain significant populations of empty or partially packaged capsids. These particles contribute to the total capsid yield but do not contribute to the full vector-genome titer.
Consequently, a production run may generate a substantial number of AAV2 particles while still producing a relatively modest yield of genome-containing vectors.
Why Super-High-Titer AAV2 Production Is Challenging
The combination of:
• strong binding to producer cells• limited release into the culture medium• relatively low recoverable vector productivity• inefficient recovery during downstream processing• formation of empty or partially packaged capsids
can make AAV2 particularly challenging to manufacture at very high yields.
For these reasons, obtaining large quantities of AAV2 at >10^13 VG/mL can require substantially more production capacity and process optimization than many higher-yielding AAV serotypes.
Important updates waiting for you!
Enter your email address below and subscribe to our newsletter